Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) EBITDA (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed EBITDA for 2 consecutive years, with -$18.1 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 49.31% to -$18.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$79.7 million through Dec 2025, down 3.26% year-over-year, with the annual reading at -$79.7 million for FY2025, 3.26% down from the prior year.
  • EBITDA for Q4 2025 was -$18.1 million at Pyxis Oncology, up from -$21.9 million in the prior quarter.
  • The five-year high for EBITDA was -$3.4 million in Q1 2024, with the low at -$35.8 million in Q4 2024.